Search
ALKS 27
go.drugbank.com/drugs/DB05752ExperimentalStudy showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
Serelaxin
go.drugbank.com/drugs/DB05794InvestigationalRecombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic … bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.
NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.
Mito-4509
go.drugbank.com/drugs/DB05846ExperimentalMito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.
Rivanicline
go.drugbank.com/drugs/DB05855ExperimentalIt has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis. … Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a partial agonist at neuronal nicotinic acetylcholine receptors, binding primarily to the α4β2 subtype.
VIT-100
go.drugbank.com/drugs/DB05865ExperimentalIn preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control.
99mTc-14 F7 Mab
go.drugbank.com/drugs/DB05867Experimental99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo. Growth inhibition and prolonged survival of the myeloma tumor were obtained as evidences of anti tumor effect after treatment with 99mTc 14F7 Mab.
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870ExperimentalThe integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial
MBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies.